Financial writers often lament that shareholders are too passive with respect to exercising their rights to oppose management decisions that they disagree with and holding management to account. Well, that can't be said about Elan's (NYSE:ELN) shareholders. Shareholders handed a significant and embarrassing collection of rejections to management, a move that I would argue expresses a very wise lack of confidence in management. With this rejection of management's strategy, I would hope that Elan management sees reason and seeks out the best deal available to sell the company.

SEE: Evaluating A Company’s Management

Back To The Drawing Board...
Regrettably, as of the time of this writing, Elan had not posted the actual voting results of the extraordinary general meeting held to give investors a say on four major proposals – the Theravance (Nasdaq:THRX) royalty agreement, the AOP acquisition, the ELND005 spin-off, and the share buyback plan. What Elan did say in an uncommonly tersely-worded press release was that shareholders had rejected the first three items and accepted only the buyback plan.

At the risk of grandstanding (and not knowing how close the votes were), I'd call this is a significant wake-up call to Elan management that shareholders are not on the same page with them and do not trust them to build value through these transactions. As I've thought each of the proposed transactions (except for the buyback) were ill-conceived and highly likely to destroy shareholder value, this is a good move for shareholders.

Insofar as I understand Elan's corporate governance rules, management does not have the option to ignore these results and proceed. I mention this only because we have seen a few examples recently of companies (not Elan) where shareholders voted against particular board nominees and the company effectively ignored or overruled the votes anyway.

SEE: Ethical Investing: Investor Activism and Shareholder Advocacy

… And Back To The Table
Given that companies always canvas major shareholders ahead of significant meetings/votes like this, Elan management had to know this rejection was coming. This is why I believe Elan announced on Friday (May 14th) that it was proceeding with a formal plant to sell the company.

It's worth noting that Royalty Pharma's bid lapsed with the shareholder approval of the share buyback. Nevertheless, Elan's management “invited” Royalty Pharma to participate in the sale process. Given that no other buyer has publicly expressed any interest in Elan, that's hardly a magnanimous gesture.

To be sure, Elan has some value (especially now that these ill-conceived transactions have been turfed). Elan received over $3 billion from Biogen Idec (Nasdaq:BIIB) for its stake in Tysabri, as well as potentially lucrative contingent payments. What's more, apart from a single pipeline asset (ELND005), there's not really much to the company, so it ought to be a fairly simple transaction to structure.

The question is whether anybody will step up with a better offer than Royalty. Valeant (NYSE:VRX) is seemingly always a potential interested party in such situations, but with the deal for Bausch + Lomb already announced, management will be busy enough (not to mention, with Elan based in Ireland, Valeant can't generate the major tax leverage that often drives the value of so many of its deals). I wouldn't be surprised if financial buyers (private equity) at least investigated a potential deal, at which point the bid price relative to Royalty Pharma would come down to the various opinions on the value of the Tysabri royalty stream and the respective costs of capital.

SEE: Trade Takeover Stocks With Merger Arbitrage

The Bottom Line
If Elan management cannot come up with transactions that its shareholders approve, the whole point of the Tysabri transaction (effectively paying a premium to pull forward the revenue stream) largely evaporates. On the other hand, the deals to acquire a royalty interest in Theravance's COPD drugs and all of orphan drug developer AOP didn't look like value-additive deals either.

For Theravance, this is an unfortunate development, as the Elan transaction basically overvalued its COPD assets. For Elan, we'll see what happens next. A buyout seems much more likely now, and barring a change of management, that would almost certainly be the best way for Elan shareholders to see maximal value for this asset.

At the time of writing, Stephen D. Simpson did not own shares in any of the companies or funds mentioned in this article.

Related Articles
  1. Fundamental Analysis

    Mergers And Acquisitions: Understanding Takeovers

    In the dramatic world of M&As, battleground terms meld with bizarre metaphors to form the language of the game.
  2. Investing Basics

    Warding Off Hostile Takeovers

    The purpose of this article is to provide a general overview of hostile corporate takeovers, while highlighting a general course of action against such activity. This article provides basic information ...
  3. Mutual Funds & ETFs

    Corporate Takeover Defense: A Shareholder's Perspective

    Find out the strategies corporations use to protect themselves from unwanted acquisitions.
  4. Options & Futures

    Pinpoint Takeovers First

    Use these seven steps to discover a takeover before the rest of the market catches on.
  5. Active Trading Fundamentals

    Trade Takeover Stocks With Merger Arbitrage

    This high-risk strategy attempts to profit from price discrepancies that arise during acquisitions.
  6. Bonds & Fixed Income

    Trademarks Of A Takeover Target

    These tips can lead you to little companies with big prospects.
  7. Insurance

    Explaining Indemnity Insurance

    Indemnity insurance is an insurance policy that protects business owners and employees from losses due to failure to deliver expected services.
  8. Retirement

    What to Do When Your Doctor Doesn't Take Medicare

    Stay and pay the full fee? Cut and run to another provider? Five ways to cope when Medicare threatens to break up you and your medico.
  9. Stock Analysis

    How Does Oscar Work and Make Money?

    Learn how startup Oscar is taking on the health insurance giants by offering customers free doctor's visits, generic drugs and 24-hour phone access to doctors.
  10. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. What role does the agency problem play in the modern Health Care industry?

    Agency problems vary from health care system to health care system, and not all economists agree on the degree and desirability ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  6. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!